natgillin/translations-raw huggingface dataset:
Not reached
ni dosežen
Not reached (1.2+, 11.1+)
ni doseženo (1,2+, 11,1+)
Not reached (1.4+, 11.5+)
ni doseženo (1,4+, 11,5+)
Not reached (1.6+, 13.8+)
ni doseženo (1,6+, 13,8+)
Not reached (11, not available)
ni doseženo (11, ni na voljo)
Not reached (13, NA)
ni doseženo (13, NP)
Not reached (14, not available)
ni doseženo (14, ni na voljo)
Not reached (2.8+, 14.3+)
ni doseženo (2,8+, 14,3+)
Not reached (NA, NA)
ni doseženo (NP, NP)
Not recommended
ni priporočena
Not Recommended
ni priporočeno
Not recommended
ni priporočila
Not recommended
ni priporočljivo
Not recommended
Sočasna uporaba ni priporočena
Not recommended as the safety and efficacy of RAVICTI in this age group has not been established.
Ni priporočljivo, saj varnost in učinkovitost zdravila RAVICTI pri otrocih v tej starostni skupini nista bili dokazani.
Not recommended because of reboxetine narrow’s therapeutic margin.
Ni priporočljivo zaradi ozkega terapevtskega okna reboksetina.
Not recommended due to an increased risk in QT prolongation.
Ni priporočljivo zaradi povečanega tveganja podaljšanja intervala QT.
Not recommended due to the increased risk of adverse events.
Ni priporočljivo zaradi povečanega tveganja neželenih dogodkov.
Not recommended due to the increased risk of QT prolongation and extrapyramidal symptoms.
Ni priporočljivo zaradi povečanega tveganja podaljšanja intervala QT in ekstrapiramidnih simptomov.
Not recommended due to the risk of increased exposure to these drugs and QT prolongation.
Ni priporočljivo zaradi tveganja povečane izpostavljenosti tem zdravilom in podaljšanja intervala QT.
Not recommended unless necessary.
Ni priporočljivo, razen če je nujno.
not recommended.
lopinavirjem/ritonavirjem ne
not recommended.
priporočljiva.
Not recommended. (See also “Effects of other medicinal products on the metabolism of Ketoconazole HRA ”)
Ni priporočljivo. (Glejte tudi »Učinki drugih zdravil na presnovo zdravila Ketokonazol HRA«.)
Not recommended/to be avoided:
Nepriporočljiva/treba se jim je izogibati:
Not recovered
Ni izboljšanja
Not relevant
Navedba smiselno ni potrebna.
Not relevant
Podatek ni potreben.
Not relevant, as INTEGRILIN is intended for use only in hospitalised patients.
Podatek ni potreben, ker je zdravilo INTEGRILIN namenjeno samo zdravljenju hospitaliziranih bolnikov.
Not reported
Ni podatka
Not reported in MCRC study; however, PRES was reported in patients from other studies treated with aflibercept as monotherapy and in combination with chemotherapies other than FOLFIRI
PRES ni bil opisan v študiji mKRR, opisan pa je bil v drugih študijah pri bolnikih, ki so bili zdravljeni z afliberceptom kot monoterapijo ali v kombinaciji z drugimi kemoterapijami razen FOLFIRI
Not Responded
Neodzivni
not shake the vial as this will cause foaming.
Viale ne stresajte, ker to povzroča penjenje.
not sleeping well
težave s spanjem,
Not statistically significant (p >0.05).
Ni statistično značilno (p >0,05).
Not statistically significant (P ≥ 0.05).
Ni statistično značilno (p ≥ 0,05).
Not statistically significant (p  0.05).
Ni statistično značilno (p >0,05).
Not statistically significant (p  0.05).
Ni statistično značilno (p  0,05).
Not statistically significant.
Meningitis
Not studied
Ni raziskano.
Not studied clinically.
CYP3A4][CYP3A4 substrates and
Not studied, but both are potent
Ni raziskano; ker pa sta oba močna
Not studied, but no interaction expected based on the primary renal elimination route for other NRTIs (e.g., abacavir, emtricitabine, lamivudine, stavudine and zidovudine).
Medsebojnih delovanj niso preiskovali, vendar jih ni pričakovati glede na to, da se ostali NRTI (npr. abakavir, emtricitabin, lamivudin, stavudin in zidovudin) izločajo predvsem skozi ledvice.
Not studied, combined administrations are expected to significantly increase concentrations of midazolam, particularly when midazolam is given orally (CYP3A4 inhibition).
Pričakuje se, da kombinirana uporaba pomembno poveča koncentracije midazolama, predvsem kadar se daje peroralno (inhibicija CYP3A4).
Not studied, no interaction expected.
Ni raziskano, medsebojno delovanje ni
Not studied.
ali rosuvastatina, če
Not studied.
brez
Not studied.
darunavir/ritonavir3
Not Studied.
eritromicina lahko
Not studied.
Invirase/ritonavirjem.
Not studied.
Mehanizem:
Not studied.
ni raziskano
Not studied.
niso preučevali
Not studied.
tavudin
Not studied.
UČINEK
Not studied:
Ni raziskan.
Not studied;
Ni raziskan;
NOT supplied in the pack
NI priloženo v pakiranju:
not supplied in the pack one sterile injection syringe with 19 (19G) or wider Gauge needle to withdraw the solvent one sterile injection syringe with 26 Gauge (26G) needle for the injection
ni priloženo pakiranju eno sterilno injekcijsko brizgo z iglo velikosti 19 G ali večjo, da izvlečete vehikel eno sterilno injekcijsko brizgo z iglo velikosti 26 G za injiciranje
Not to attempt to disrupt the injected cord by self-manipulation at any time.
vozliča, dokler postopek iztegovanja prstov ne bo zaključen,
Not to be sold separately. vials with powder and 15 pre-filled syringes with 1.2 ml solvent.
Ni namenjeno ločeni prodaji. vial s praškom in 15 napolnjenih injekcijskih brizg z 1,2 ml vehikla.
Not to donate blood during treatment and for 24 months after the final dose
Da ne smejo darovati krvi med zdravljenjem in 24 mesecev po končanem zdravljenju
Not to donate blood during treatment and for at least 20 months after the final dose
opozorilo, naj ne darujejo krvi v času zdravljenja in še najmanj 20 mesecev po prejemu zadnjega odmerka
Not to donate organs nor blood nor cells
Prepoved darovanja organov, krvi in celic
not to donate organs nor blood nor cells
prepovedi darovanja organov, krvi in celic;
Not to flex or extend the fingers of the injected hand to reduce extravasation of Xiapex out of the cord until the finger extension procedure is completed.
pregledal roko in izvedel postopek iztegovanja prstov za prekinitev vozliča, naj ne krčijo ali iztegujejo prstov zdravljene roke, da ne bi zdravilo Xiapex uhajalo ven iz
Not to give Erivedge to any other person
Opozorilo, da zdravila Erivedge ne dajejo drugim
Not to prescribe to patients with pre-existing severe hepatic disease
opozorilo, da se bolnikom s predhodno hudo boleznijo jeter zdravila ne sme predpisati,
Not to take Lojuxta if patient has liver problems, or unexplained abnormal liver tests;
Ne jemljite zdravila Lojuxta, če imate težave z jetri ali nenormalne rezultate preiskav jetrnega delovanja;
Not to use Instanyl nasal spray for treatment of more than four breakthrough cancer pain episodes a day.
Ne uporabljati Instanyl pršila za nos za zdravljenje več kot štirih epizod prebijajoče bolečine zaradi raka na dan.
Not to use Instanyl nasal spray to treat any other kind of pain, such as headaches, back pain or toothache.
Ne uporabljati Instanyl pršila za nos za zdravljenje drugih vrst bolečine, kot so glavobol, bolečina v križu ali zobobol.
not tolerated.
Skupna vrednost
Not within the scope of Council Regulation 2377/90
Ni v okviru Odredbe sveta 2377/90
notable adverse reactions associated with efavirenz are rash and nervous system symptoms.
Najopaznejši neželeni učinki, povezani z efavirenzem, so izpuščaj in simptomi živčnega sistema.
Notable differences in the MCL patient population as compared to patients in the multiple myeloma studies were a ≥ 5% higher incidence of the haematological adverse reactions (neutropenia, thrombocytopenia, leukopenia, anaemia, lymphopenia), peripheral sensory neuropathy, hypertension, pyrexia, pneumonia, stomatitis, and hair disorders.
Opazne razlike v populaciji bolnikov z MCL v primerjavi z bolniki v študijah diseminiranega plazmocitoma so bile ≥ 5% večja pojavnost hematoloških neželenih učinkov (nevtropenija, trombocitopenija, levkopenija, anemija, limfopenija), periferna senzorična nevropatija, hipertenzija, zvečana telesna temperatura, pljučnica, stomatitis in bolezni las.
Notable differences in the MCL patient population as compared to patients in the multiple myeloma studies were a ≥ 5% higher incidence of the haematological adverse reactions (neutropenia, thrombocytopenia, leukopenia, anemia, lymphopenia), peripheral sensory neuropathy, hypertension, pyrexia, pneumonia, stomatitis, and hair disorders.
Opazne razlike v populaciji bolnikov z MCL v primerjavi z bolniki v študijah diseminiranega plazmocitoma so bile ≥ 5 % večja pojavnost hematoloških neželenih učinkov (nevtropenija, trombocitopenija, levkopenija, anemija, limfopenija), periferna senzorična nevropatija, hipertenzija, zvečana telesna temperatura, pljučnica, stomatitis in bolezni las.
Notably, 22% of patients reported a complete cytogenetic response (CCyR) in the dasatinib arm while only 8% achieved a CCyR in the imatinib arm.
O popolnem citogenetskem odzivu so poročali pri 22% bolnikov v skupini, ki je prejemala dasatinib in le pri 8% bolnikov v skupini, ki je prejemala imatinib.
Note 1: At 80 MHz and 800 MHz, the higher frequency range applies.
Opomba 1: Pri 80 MHz in 800 MHz se uporablja višje frekvenčno območje.
Note 1: At 80 MHz and 800 MHz, the separation distance for the higher frequency range applies.
Opomba 1: Pri 80 MHz in 800 MHz se uporablja višje frekvenčno območje.
Note 1: In adult patients 1st dose reduction of ribavirin is by 200 mg/day (except in patients receiving the 1,400 mg, dose reduction should be by 400 mg/day).
Opomba 1: Pri odraslih bolnikih je prvo zmanjšanje odmerka ribavirina za 200 mg/dan (razen pri bolnikih, ki prejemajo 1.400 mg - pri njih odmerek zmanjšajte za 400 mg/dan).
Note 1: In adult patients, 1st dose reduction of Ribavirin BioPartners is by 200 mg/day (except in patients receiving the 1,400 mg, dose reduction should be by 400 mg/day).
Opomba 1: Prvo zmanjšanje odmerka zdravila Ribavirin BioPartners pri odraslih bolnikih naj bo za 200 mg/dan (razen pri bolnikih, ki prejemajo 1.400 mg – pri njih odmerek zmanjšajte za 400 mg/dan).
Note 1: In adult patients, 1st dose reduction of Ribavirin Teva Pharma B.V. is by 200 mg/day (except in patients receiving the 1,400 mg, dose reduction should be by 400 mg/day).
Opomba 1: Prvo zmanjšanje odmerka zdravila Ribavirin Teva Pharma B.V. pri odraslih bolnikih naj bo za 200 mg/dan (razen pri bolnikih, ki prejemajo 1.400 mg - pri njih odmerek zmanjšajte za 400 mg/dan).
Note 2: In adult patients 1st dose reduction of PegIntron is to 1 µg/kg/week.
Opomba 2: Pri odraslih bolnikih je prvo zmanjšanje odmerka zdravila PegIntron na 1 µg/kg/teden.
Note 2: In adult patients 1st dose reduction of ViraferonPeg is to 1 µg/kg/week.
Opomba 2: Pri odraslih bolnikih je prvo zmanjšanje odmerka zdravila ViraferonPeg na 1 µg/kg/teden.
Note 2: In adult patients and children and adolescent patients treated with Rbavirin Teva Pharma B.V. plus interferon alfa-2b, reduce the interferon alfa-2b dose by one-half dose.
Opomba 2: Pri odrasli bolnikih, zdravljenih z zdravilom Ribavirn Teva in interferonom alfa-2b zmanjšajte odmerek interferona alfa-2b za polovico.
Note 2: In adult patients and children and adolescent patients treated with Rbavirin Teva Pharma B.V. plus interferon alfa-2b, reduce the interferon alfa-2b dose by one-half dose.
Opomba 2: Pri odrasli bolnikih, zdravljenih z zdravilom Ribavirn Teva Pharma B.V. in interferonom alfa-2b zmanjšajte odmerek interferona alfa-2b za polovico.
Note 2: In adult patients and children and adolescent patients treated with Ribavirin BioPartners plus interferon alfa-2b, reduce the interferon alfa-2b dose by one-half dose.
Opomba 2: Pri odraslih bolnikih ter pri otrocih in mladostnikih, zdravljenih z zdravilom Ribavirin BioPartners in interferonom alfa-2b, zmanjšajte odmerek interferona alfa-2b na polovico.
Note 2: These guidelines may not apply in all situations.
Opomba 2: Te smernice ne veljajo v vseh situacijah.
Note 3: An additional factor of 10/3 is used in calculating the recommended separation distance to decrease the likelihood that mobile/portable communications equipment could cause interference if it is inadvertently brought into patient areas.
Opomba 3: Faktor 10/3 se uporabi pri izračunu priporočene varnostne razdalje, da bi se zmanjšala možnost, da bi mobilna komunikacijska oprema povzročala motnje v primeru, da je taka oprema nehote prinešena v bližino bolnika.
Note albumin-corrected serum calcium concentrations are calculated as follows:
Opomba: koncentracije korigiranega kalcija v serumu izračunamo po naslednji formuli:
Note that foaming of the solution may occur.
Naj opozorimo, da se raztopina pri tem lahko peni.
Note that Myocet may be administered through a central or peripheral vein.
Ne pozabite, da zdravilo Myocet lahko daste v osrednjo ali v periferno veno.
Note that the injection button only goes out as far as the amount of insulin that is left in the reservoir.
Gumb za injiciranje gre ven le toliko, koliko insulina je še v rezervoarju.
Note that the injection button only goes out as far as the amount of insulin that is left in the reservoir.
Gumb za injiciranje gre ven le toliko, kolikor insulina je še v rezervoarju.
Note that the virologic stopping rules taken into account in this treatment outcome analysis are actual stopping rules, i.e., those derived from disposition and exposure data, as opposed to mathematical stopping rules, i.e., derived from the HCV RNA data.
Opomba: v analizi zdravljenja so upoštevani dejanski kriteriji za prekinitev zdravljenja (kriteriji na osnovi bolezni in podatkov o izpostavljenosti) in ne kriterijev določenih na osnovi podatkov o koncentraciji HCV RNK.
Note that this is likely to be an underestimate since docetaxel alone at a dose of 100 mg/m2 is known to result in neutropenia in 97% of patients, 76% grade 4, based on nadir blood counts.
Upoštevajte, da je to verjetno podcenjen deleţ, kajti znano je, da sam docetaksel v odmerku 100 mg/m2 povzroči nevtropenijo pri 97 % bolnikov, 76 % stopnje 4, na podlagi najniţjega števila celic v krvi.
Note that Trocoxil has an extended effect of duration (up to 2 months after administration of the second dose and following doses).
Trocoxil ima podaljšano delovanje (do 2 meseca po dajanju drugega odmerka in sledečih odmerkih).
Note the time the patient drinks the test meal.
Zabeležite čas, ob katerem bolnik zaužije testni obrok.
Note the time upon drinking.
Ko popijete raztopino, morate zabeležiti točen čas.
Note then that co-administration of tenofovir disoproxil fumarate and didanosine is not recommended as it results in a 40-60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse reactions.
Treba je opozoriti, da sočasna uporaba dizoproksiltenofovirijevega fumarata in didanozina ni priporočljiva, saj povzroča povečanje sistemske izpostavljenosti didanozinu za 40–60%, kar lahko poveča tveganje za pojav neželenih učinkov, povezanih z didanozinom (glejte poglavje 4.5).
Note time patient drinks test meal
Zabeležite čas, kdaj je bolnik popil tesni obrok
Note – If you are unable to start the injection as described, press the pen more firmly against your skin, then press the green button again.
Opozorilo – Če ne morete začeti injiciranja, kakor je opisano, peresnik močneje pritisnite ob kožo in nato znova pritisnite zeleni gumb.
Note1
opombe1
NOTE:
OPOZORILO:
Note: 501 (2 g CellCept daily) and 277 (2 g IV / 3 g oral CellCept daily) patients were treated in Phase III studies for the prevention of rejection in renal and hepatic transplantation, respectively.
Opomba: V III. fazi študij preprečevanja zavrnitve ledvičnega in jetrnega presadka so vključili 501 (2 g zdravila CellCept na dan) in 277 (2 g i.v./3 g peroralne oblike zdravila CellCept na dan) bolnikov.
Note: 501 (2 g CellCept daily), 289 (3 g CellCept daily) and 277 (2 g IV / 3 g oral CellCept daily) patients were treated in Phase III studies for the prevention of rejection in renal, cardiac and hepatic transplantation, respectively.
Opomba: V III. fazi študij preprečevanja zavrnitve ledvičnega, srčnega in jetrnega presadka so vključili 501 (2 g zdravila CellCept na dan), 289 (3 g zdravila CellCept na dan) in 277 (2 g i.v./3 g peroralne oblike zdravila CellCept na dan) bolnikov.
Note: 501 (2 g mycophenolate mofetil daily), 289 (3 g mycophenolate mofetil daily) and 277 (2 g intravenous / 3 g oral mycophenolate mofetil daily) patients were treated in Phase III studies for the prevention of rejection in renal, cardiac and hepatic transplantation, respectively.
Opomba: 501 (2 g mofetilmikofenolata dnevno), 289 (3 g mofetilmikofenolata dnevno) in 277 (2 g intravenozno / 3 g mofetilmikofenolata peroralno dnevno) bolnikov je bilo zdravljenih v III. fazi kliničnih preiskušanj za preprečitev zavrnitve ledvičnega, srčnega oziroma jetrnega presadka.
Note: A small air bubble will not harm you or affect your dose.
Opomba: Majhen zračni mehurček v vložku je običajen.
Note: A subject can be included in multiple sub-categories if he/she had an event for those categories.
Opomba: Preiskovanka/-ec je lahko zajet v več podkategorijah, če je imel/-a dogodek, ki ustreza tistim kategorijam.
Note: a.
Opomba: a.
Note: Adverse reactions are reported using MedDRA version MEDDRA13.1 and graded using NCI CTC version 3.0
Opomba: Neželeni učinki so navedeni z uporabo MedDRA verzija MEDDRA 13.1 in stopenj po NCI CTC verzija 3.0
Note: After injecting the water into the vial it is common for the plunger to move back up.
Opomba: Po injiciranju vode v vialo se bat pogosto premakne nazaj gor.
Note: all patients in the DUET trials received a background regimen consisting of darunavir/rtv, investigator-selected NRTIs and optional enfuvirtide.
Opomba: Vsi bolniki iz preskušanj DUET so prejemali osnovno shemo: darunavir/ritonavir, NRTI po izbiri raziskovalca in enfuvirtid po izbiri.
Note: An OR > 1 indicates an advantage for bortezomib-containing induction therapy
Opomba: OR > 1 kaže na prednost uvajalnega zdravljenja z B.
Note: An OR > 1 indicates an advantage for bortezomib-containing induction therapy.
Opomba: OR > 1 kaže na prednost uvajalnega zdravljenja z Bz.
Note: An OR > 1 indicates an advantage for Bz-containing induction therapy
Opomba: OR > 1 kaže na prednost uvajalnega zdravljenja z Bz.
Note: An OR > 1 indicates an advantage for Bzmb-containing induction therapy
Opomba: OR > 1 kaže na prednost uvajalnega zdravljenja z Bzmb.
Note: An OR > 1 indicates an advantage for Vc-containing induction therapy
Opomba: OR > 1 kaže na prednost uvajalnega zdravljenja z Vc.
Note: Based on a population pharmacokinetic analysis in 112 immunocompromised paediatric patients aged 2 to <12 years and 26 immunocompromised adolescents aged 12 to <17 years.
Opomba: Na podlagi populacijske farmakokinetične analize pri 112 imunsko oslabelih otrocih, starih od 2 do < 12 let, in 26 imunsko oslabelih mladostnikih, starih od 12 do < 17 let.
Note: Baseline mutations were identified before the patient's first dose of study drug. a The percentage is based on number of patients with baseline mutation assessment. b The evaluable population includes patients who had a valid baseline disease assessment. c 1 subject had more than 1 mutation in this category.
Opomba: Mutacije ob izhodišču so bile ugotovljene, preden je bolnik prejel prvi odmerek študijskega zdravila. a Odstotek temelji na številu bolnikov z oceno mutacij na začetku študije. b Populacija, ki jo je bilo mogoče oceniti, vključuje bolnike z veljavno oceno bolezni na začetku študije. c En preiskovanec je imel več kot eno mutacijo v tej kategoriji.
Note: CI=Confidence interval; IRAC=Independent Review Adjudication Committee; NE = Not Estimable. a The median is based on Kaplan-Meier estimate.
Opomba: IZ = interval zaupanja; IRAC = Neodvisni presojevalni odbor (Independent Review Adjudication Committee); NE = ni mogoče oceniti. a Mediana temelji na oceni Kaplan-Meier.
NOTE: do not use any areas in which you feel lumps, firm knots, or pain; talk to your doctor or healthcare professional about anything you find.
OPOMBA: Ne uporabljajte predelov, v katerih čutite zatrdline, trdne vozle ali bolečino; o vsem, kar opazite, se pogovorite s svojim zdravnikom ali drugim zdravstvenim delavcem.
NOTE: Do not use the same area each day for each injection - rotate sites (use upper, lower, and left and right side of your belly) to avoid discomfort.
OPOZORILO: Ne uporabljajte istega področja za injekcijo vsak dan– izmenjujte vbodna mesta (uporabite zgornji, spodnji, levi in desni del trebuha) v izogib nelagodju.
Note: Doses used for Viekirax and dasabuvir were: ombitasvir 25 mg, paritaprevir 150 mg, ritonavir 100 mg, once daily and dasabuvir 400 mg twice daily or 250 mg twice daily.
Opomba: Uporabljeni odmerki zdravila Viekirax in dasabuvirja so bili: ombitasvir 25 mg, paritaprevir 150 mg, ritonavir 100 mg enkrat na dan in dasabuvir 400 mg dvakrat na dan ali 250 mg dvakrat na dan.
Note: For a 300 mg dose, prepare 2 pre-filled syringes and inject the contents of both.
Opomba: Za odmerek 300 mg pripravite 2 napolnjeni injekcijski brizgi in injicirajte vsebino obeh.
Note: For mantle cell lymphoma, multiple vials will be required for each dose over 25 mg.
Opozorilo: Pri limfomu plaščnih celic bo za vsak odmerek, večji od 25 mg, potrebnih več vial.
Note: For patients who weigh < 47 kg, or are unable to swallow tablets, ribavirin oral solution is available and should be used if appropriate).
Opomba: Za bolnike, ki tehtajo < 47 kg ali ne morejo pogoltniti tablete, je na voljo peroralna raztopina ribavirina.
Note: For patients who weigh <47kg, or are unable to swallow capsules, ribavirin oral solution is available and should be used if appropriate).
Opomba Za bolnike, ki tehtajo < 47 kg ali ne morejo pogoltniti tablete, je na voljo peroralna raztopina ribavirina.
Note: Grip at the yellow hub of the injection needle while removing the cap.
Pozor: Pri odstranjevanju pokrovčka držite injekcijsko iglo za rumeni obod.
Note: If there is any colour or particles in the liquid, contact your healthcare professional.
Opomba: Če je tekočina kakor koli obarvana ali so v njej delci, se posvetujte z zdravstvenim delavcem.
Note: If you are unable to inhale correctly after several attempts, consult your doctor.
Opomba: Če vam po več poskusih ne uspe vdihniti pravilno, se posvetujte z zdravnikom.
Note: If you need to use more than one pre-filled syringe of ReFacto AF per infusion, each syringe should be reconstituted according to the specific directions.
Opomba: Če morate uporabiti več kot eno napolnjeno injekcijsko brizgo zdravila ReFacto AF na infuzijo, morate vsako brizgo pripraviti po navedenih navodilih.
Note: If you use more than one vial of ReFacto AF per infusion, each vial should be reconstituted as per the previous instructions.
Opomba: Če morate uporabiti več kot eno vialo zdravila ReFacto AF na infuzijo, morate vsako vialo pripraviti po navedenih navodilih.
Note: If your Genuair inhaler appears to be damaged or if you lose the cap, your inhaler should be replaced.
Opomba: Če se inhalator Genuair poškoduje ali izgubite pokrovček, ga je treba zamenjati.
Note: If your Genuair inhaler appears to be damaged or if you lose the cap, your inhaler should be replaced.
Opomba: Če se inhalator Genuair poškoduje ali izgubite pokrovček, ga morate zamenjati.
Note: If your healthcare professional has instructed you that your Nplate dose requires more than one injection of Nplate, you will need to use more than one self injection kit.
Opomba: Če vam je zdravstveni delavec dal navodila, da za svoj odmerek zdravila Nplate potrebujete več kot eno injekcijo zdravila Nplate, boste morali uporabiti več kot le en komplet za samoinjiciranje.
Note: Imputation was applied to intermittent missing data.
Opomba: za občasne manjkajoče podatke je bila uporabljena imputacija.
Note: In drug-drug interaction studies, different formulations and/or doses of etravirine were used which led to similar exposures and, therefore, interactions relevant for one formulation are relevant for the other.
Opomba: v študijah medsebojnih delovanj med zdravili so uporabljali različne oblike in/ali odmerke etravirina, s čimer so dosegli podobne stopnje izpostavljenosti, zato veljajo medsebojna delovanja, ki se nanašajo na eno obliko, hkrati tudi za drugo.
Note: Includes all patients who received at least 1 injection of double-blind study medicinal product (Xiapex 0.58 mg or placebo).
Opomba: vključuje vse bolnike, ki so prejeli vsaj eno injekcijo dvojno slepega zdravila v kliničnem preskušanju (Xiapex 0,58 mg ali placebo).